Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Depreciation and Depletion: 2022-2025

Historic Depreciation and Depletion for Dianthus Therapeutics (DNTH) over the last 3 years, with Sep 2025 value amounting to $27,000.

  • Dianthus Therapeutics' Depreciation and Depletion rose 8.00% to $27,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $110,000, marking a year-over-year increase of 22.22%. This contributed to the annual value of $96,000 for FY2024, which is 43.28% up from last year.
  • As of Q3 2025, Dianthus Therapeutics' Depreciation and Depletion stood at $27,000, which was down 10.00% from $30,000 recorded in Q2 2025.
  • Dianthus Therapeutics' Depreciation and Depletion's 5-year high stood at $30,000 during Q2 2025, with a 5-year trough of $6,000 in Q3 2022.
  • For the 3-year period, Dianthus Therapeutics' Depreciation and Depletion averaged around $22,545, with its median value being $23,000 (2024).
  • Data for Dianthus Therapeutics' Depreciation and Depletion shows a peak YoY soared of 216.67% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Dianthus Therapeutics' Depreciation and Depletion stood at $11,000 in 2022, then surged by 81.82% to $20,000 in 2023, then soared by 30.00% to $26,000 in 2024, then increased by 8.00% to $27,000 in 2025.
  • Its last three reported values are $27,000 in Q3 2025, $30,000 for Q2 2025, and $27,000 during Q1 2025.